Trials / Completed
CompletedNCT00156884
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Alberta Health services · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Detailed description
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | strontium-89 | |
| DRUG | cisplatin |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2005-09-12
- Last updated
- 2012-01-19
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00156884. Inclusion in this directory is not an endorsement.